Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23622821 | 1.00 | OAT (0.55) | OATCES2LMNATSHRNPC1 | |
| SCHEMBL23622816 | 1.00 | OAT (0.55) | OATCES2LMNATSHRNPC1 | |
| SCHEMBL23622744 | 0.82 | OAT (0.36) | OATLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL23622730 | 0.82 | OAT (0.36) | OATLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL23622707 | 0.82 | OAT (0.36) | OATLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL23622728 | 0.77 | RAB9A (0.40) | LMNANPC1ALDH1A1GAAMAPT | |
| SCHEMBL23622822 | 0.77 | RAB9A (0.40) | LMNANPC1ALDH1A1GAAMAPT | |
| SCHEMBL23622826 | 0.77 | RAB9A (0.40) | LMNANPC1ALDH1A1GAAMAPT | |
| SCHEMBL6372307 | 0.75 | OAT (0.60) | OATCES2LMNATSHRNPC1 | |
| SCHEMBL6518383 | 0.72 | OAT (0.62) | OATCES2LMNATSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206714-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206714-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PMP22, GABBR1, GABBR2 | OAT 421/4885CES2 4169/4885LMNA 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.